Table of Contents

1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources

2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

3. Oncology Companion Diagnostic Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.1.1. Growing Adoption of Companion Diagnostics Push the Growth of the Market
3.3.2. Market Restraints Analysis
3.3.2.1. Biomarker Identification and Validation and Intellectual Property and Licensing May Impede the Growth of the Market
3.4. Oncology Companion Diagnostic Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape

4. Oncology Companion Diagnostic Market: Offering & Services Estimates & Trend Analysis

4.1. Offering and Services Market Share, 2025 & 2033
4.2. Segment Dashboard
4.3. Oncology Companion Diagnostic Market by Offering & Services Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2024 to 2033 for the following
4.5. Product
4.5.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
4.5.2. Instrument
4.5.2.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
4.5.3. Consumables
4.5.3.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
4.5.4. Software
4.5.4.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
4.6. Services
4.6.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)

5. Oncology Companion Diagnostic Market: Technology Estimates & Trend Analysis

5.1. Technology Market Share, 2025 & 2033
5.2. Segment Dashboard
5.3. Oncology Companion Diagnostic Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2024 to 2033 for the following
5.5. Polymerase Chain Reaction (PCR)
5.5.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
5.6. Next-generation Sequencing (NGS)
5.6.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
5.7. Immunohistochemistry (IHC)
5.7.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
5.8. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
5.8.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
5.9. Other Technologies
5.9.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)

6. Oncology Companion Diagnostic Market: Disease Type Estimates & Trend Analysis

6.1. Disease Type Market Share, 2025 & 2033
6.2. Segment Dashboard
6.3. Oncology Companion Diagnostic Market by Disease Type Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2024 to 2033 for the following
6.5. Breast Cancer
6.5.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
6.6. Non-small Cell Lung Cancer
6.6.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
6.7. Colorectal Cancer
6.7.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
6.8. Leukemia
6.8.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
6.9. Melanoma
6.9.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
6.10. Prostate Cancer
6.10.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
6.11. Others
6.11.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)

7. Oncology Companion Diagnostic Market: End Use Estimates & Trend Analysis

7.1. End Use Market Share, 2025 & 2033
7.2. Segment Dashboard
7.3. Oncology Companion Diagnostic Market by Disease Type Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2024 to 2033 for the following
7.5. Hospital
7.5.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
7.6. Pathology/Diagnostic Laboratory
7.6.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
7.7. Academic Medical Center
7.7.1. Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)

8. Oncology Companion Diagnostic Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2025 & 2033
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts, Trend Analysis, 2024 to 2033:
8.5. North America
8.5.1. North America: SWOT Analysis
8.5.2. U.S.
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework
8.5.2.3. Competitive scenario
8.5.2.4. U.S. market estimates and forecasts 2024 to 2033, (USD Million)
8.5.3. Canada
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework
8.5.3.3. Competitive scenario
8.5.3.4. Canada market estimates and forecasts 2024 to 2033, (USD Million)
8.5.4. Mexico
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework
8.5.4.3. Competitive scenario
8.5.4.4. Canada market estimates and forecasts 2024 to 2033, (USD Million)
8.6. Europe
8.6.1. Europe: SWOT Analysis
8.6.2. UK
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework
8.6.2.3. Competitive scenario
8.6.2.4. UK market estimates and forecasts 2024 to 2033, (USD Million)
8.6.3. Germany
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework
8.6.3.3. Competitive scenario
8.6.3.4. Germany market estimates and forecasts 2024 to 2033, (USD Million)
8.6.4. France
8.6.4.1. Key country dynamics
8.6.4.2. Regulatory framework
8.6.4.3. Competitive scenario
8.6.4.4. France market estimates and forecasts 2024 to 2033, (USD Million)
8.6.5. Italy
8.6.5.1. Key country dynamics
8.6.5.2. Regulatory framework
8.6.5.3. Competitive scenario
8.6.5.4. Italy market estimates and forecasts 2024 to 2033, (USD Million)
8.6.6. Spain
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework
8.6.6.3. Competitive scenario
8.6.6.4. Spain market estimates and forecasts 2024 to 2033, (USD Million)
8.6.7. Norway
8.6.7.1. Key country dynamics
8.6.7.2. Regulatory framework
8.6.7.3. Competitive scenario
8.6.7.4. Norway market estimates and forecasts 2024 to 2033, (USD Million)
8.6.8. Sweden
8.6.8.1. Key country dynamics
8.6.8.2. Regulatory framework
8.6.8.3. Competitive scenario
8.6.8.4. Sweden market estimates and forecasts 2024 to 2033, (USD Million)
8.6.9. Denmark
8.6.9.1. Key country dynamics
8.6.9.2. Regulatory framework
8.6.9.3. Competitive scenario
8.6.9.4. Denmark market estimates and forecasts 2024 to 2033, (USD Million)
8.7. Asia Pacific
8.7.1. Asia Pacific: SWOT Analysis
8.7.2. Japan
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework
8.7.2.3. Competitive scenario
8.7.2.4. Japan market estimates and forecasts 2024 to 2033, (USD Million)
8.7.3. China
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework
8.7.3.3. Competitive scenario
8.7.3.4. China market estimates and forecasts 2024 to 2033, (USD Million)
8.7.4. India
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework
8.7.4.3. Competitive scenario
8.7.4.4. India market estimates and forecasts 2024 to 2033, (USD Million)
8.7.5. Australia
8.7.5.1. Key country dynamics
8.7.5.2. Regulatory framework
8.7.5.3. Competitive scenario
8.7.5.4. Australia market estimates and forecasts 2024 to 2033, (USD Million)
8.7.6. South Korea
8.7.6.1. Key country dynamics
8.7.6.2. Regulatory framework
8.7.6.3. Competitive scenario
8.7.6.4. South Korea market estimates and forecasts 2024 to 2033, (USD Million)
8.7.7. Thailand
8.7.7.1. Key country dynamics
8.7.7.2. Regulatory framework
8.7.7.3. Competitive scenario
8.7.7.4. Thailand market estimates and forecasts 2024 to 2033, (USD Million)
8.8. Latin America
8.8.1. Latin America: SWOT Analysis
8.8.2. Brazil
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework
8.8.2.3. Competitive scenario
8.8.2.4. Brazil market estimates and forecasts 2024 to 2033, (USD Million)
8.8.3. Argentina
8.8.3.1. Key country dynamics
8.8.3.2. Regulatory framework
8.8.3.3. Competitive scenario
8.8.3.4. Argentina market estimates and forecasts 2024 to 2033, (USD Million)
8.9. MEA
8.9.1. MEA: SWOT Analysis
8.9.2. South Africa
8.9.2.1. Key country dynamics
8.9.2.2. Regulatory framework
8.9.2.3. Competitive scenario
8.9.2.4. South Africa market estimates and forecasts 2024 to 2033, (USD Million)
8.9.3. Saudi Arabia
8.9.3.1. Key country dynamics
8.9.3.2. Regulatory framework
8.9.3.3. Competitive scenario
8.9.3.4. Saudi Arabia market estimates and forecasts 2024 to 2033, (USD Million)
8.9.4. UAE
8.9.4.1. Key country dynamics
8.9.4.2. Regulatory framework
8.9.4.3. Competitive scenario
8.9.4.4. UAE market estimates and forecasts 2024 to 2033, (USD Million)
8.9.5. Kuwait
8.9.5.1. Key country dynamics
8.9.5.2. Regulatory framework
8.9.5.3. Competitive scenario

9. Competitive Landscape

9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Heat Map Analysis
9.4. Company Profiles
9.4.1. Abbott Laboratories
9.4.1.1. Participant’s Overview
9.4.1.2. Financial Performance
9.4.1.3. Offering Benchmarking
9.4.1.4. Recent Developments/ Strategic Initiatives
9.4.2. Agilent Technologies
9.4.2.1. Participant’s Overview
9.4.2.2. Financial Performance
9.4.2.3. Offering Benchmarking
9.4.2.4. Recent Developments/ Strategic Initiatives
9.4.3. BioMérieux
9.4.3.1. Participant’s Overview
9.4.3.2. Financial Performance
9.4.3.3. Offering Benchmarking
9.4.3.4. Recent Developments/ Strategic Initiatives
9.4.4. Biocartis
9.4.4.1. Participant’s Overview
9.4.4.2. Financial Performance
9.4.4.3. Offering Benchmarking
9.4.4.4. Recent Developments/ Strategic Initiatives
9.4.5. Bio-Rad Laboratories
9.4.5.1. Participant’s Overview
9.4.5.2. Financial Performance
9.4.5.3. Offering Benchmarking
9.4.5.4. Recent Developments/ Strategic Initiatives
9.4.6. EntroGen
9.4.6.1. Participant’s Overview
9.4.6.2. Financial Performance
9.4.6.3. Offering Benchmarking
9.4.6.4. Recent Developments/ Strategic Initiatives
9.4.7. F. Hoffmann-La Roche
9.4.7.1. Financial Performance
9.4.7.2. Offering Benchmarking
9.4.7.3. Recent Developments/ Strategic Initiatives
9.4.8. Foundation Medicine
9.4.8.1. Participant’s Overview
9.4.8.2. Financial Performance
9.4.8.3. Offering Benchmarking
9.4.8.4. Recent Developments/ Strategic Initiatives
9.4.9. Guardant Health
9.4.9.1. Participant’s Overview
9.4.9.2. Financial Performance
9.4.9.3. Offering Benchmarking
9.4.9.4. Recent Developments/ Strategic Initiatives
9.4.10. Illumina
9.4.10.1. Participant’s Overview
9.4.10.2. Financial Performance
9.4.10.3. Offering Benchmarking
9.4.10.4. Recent Developments/ Strategic Initiatives
9.4.11. Leica Biosystems
9.4.11.1. Participant’s Overview
9.4.11.2. Financial Performance
9.4.11.3. Offering Benchmarking
9.4.11.4. Recent Developments/ Strategic Initiatives
9.4.12. Myriad Genetic
9.4.12.1. Participant’s Overview
9.4.12.2. Financial Performance
9.4.12.3. Offering Benchmarking
9.4.12.4. Recent Developments/ Strategic Initiatives
9.4.13. QIAGEN
9.4.13.1. Participant’s Overview
9.4.13.2. Financial Performance
9.4.13.3. Offering Benchmarking
9.4.13.4. Recent Developments/ Strategic Initiatives
9.4.14. Sysmex Corporation
9.4.14.1. Participant’s Overview
9.4.14.2. Financial Performance
9.4.14.3. Offering Benchmarking
9.4.14.4. Recent Developments/ Strategic Initiatives
9.4.15. Thermo Fisher Scientific
9.4.15.1. Participant’s Overview
9.4.15.2. Financial Performance
9.4.15.3. Offering Benchmarking
9.4.15.4. Recent Developments/ Strategic Initiatives
9.4.16. Others
9.4.16.1. Participant’s Overview
9.4.16.2. Financial Performance
9.4.16.3. Offering Benchmarking